Red Light Holland Corp. TRIP.CN
Health Care · Pharmaceuticals, Biotechnology & Life Sciences · CSE · Canada · redlight.co
Legal-psychedelics company selling psilocybin truffles and grow kits in the Netherlands and, via its April 2026 acquisition of Filament Health Corp., developing pharmaceutical-grade natural psilocybin drug candidates led by PEX010. A rename to Rhelion Life Sciences Corp is pending CSE approval.
Key ratios
FreeCashFlowOnSale TTM -0.64
FreeCashFlowOnSale 2025 -0.41
FreeCashFlowOnSale 2024 -0.83
FreeCashFlowOnSale 2023 -1.63
NetIncomeMargin TTM -1.19
NetIncomeMargin 2025 -0.82
NetIncomeMargin 2024 -1.61
NetIncomeMargin 2023 -1.37
ReturnOnAssets TTM -0.14
ReturnOnAssets 2025 -0.12
ReturnOnAssets 2024 -0.14
ReturnOnAssets 2023 -0.1
ReturnOnEquity TTM -0.31
ReturnOnEquity 2025 -0.23
ReturnOnEquity 2024 -0.33
ReturnOnEquity 2023 -0.21
TotalRevenueYoYGrowth 2025 0.04
TotalRevenueYoYGrowth 2024 0.2
TotalRevenueYoYGrowth 2023 0.7
Recent news
Red Light Holland Reports Fiscal 2026 Audited Year-End Results and Provides Update on Rhelion Life Sciences
2026-07-29 · Newsfile
Red Light Holland Announces New Filament Health PEX010 European Research Shipment
2026-07-16 · Newsfile